



Article

# Inbreeding and Gallbladder Cancer Risk: Homozygosity Associations Adjusted for Indigenous American Ancestry, BMI, and Genetic Risk of Gallstone Disease

Francisco Ceballos <sup>1,2,\*</sup>, Felix Boekstegers <sup>1</sup>, Dominique Scherer <sup>1</sup>, Carol Barahona Ponce <sup>1</sup>, Katherine Marcelain <sup>3</sup>, Valentina Gárate-Calderón <sup>1,3</sup>, Melanie Waldenberger <sup>4</sup>, Erik Morales <sup>5,6</sup>, Armando Rojas <sup>6</sup>, César Muñoz <sup>5,6</sup>, Javier Retamales <sup>7</sup>, Gonzalo de Toro <sup>8,9</sup>, Allan Vera Kortmann <sup>8</sup>, Olga Barajas <sup>3,10</sup>, María Teresa Rivera <sup>11</sup>, Analía Cortés <sup>11</sup>, Denisse Loader <sup>12</sup>, Javiera Saavedra <sup>12</sup>, Lorena Gutiérrez <sup>13</sup>, Alejandro Ortega <sup>14</sup>, María Enriqueta Bertrán <sup>15</sup>, Leonardo Bartolotti <sup>16</sup>, Fernando Gabler <sup>17</sup>, Mónica Campos <sup>17</sup>, Juan Alvarado <sup>18</sup>, Fabricio Moisán <sup>18</sup>, Loreto Spencer <sup>18</sup>, Bruno Nervi <sup>19</sup>, Daniel Carvajal-Hausdorf <sup>20</sup>, Héctor Losada <sup>21</sup>, Mauricio Almau <sup>22</sup>, Plinio Fernández <sup>22</sup>, Jordi Olloquequi <sup>23,24</sup>, Pamela Salinas <sup>25</sup> and Justo Lorenzo Bermejo <sup>1,26,\*</sup>

<sup>1</sup> Statistical Genetics Research Group, Institute of Medical Biometry, Heidelberg University, Im Neuenheimer Feld 130.3, 69120 Heidelberg, Germany; boekstegers@imbi.uni-heidelberg.de (F.B.); scherer@imbi.uni-heidelberg.de (D.S.); barahona@imbi.uni-heidelberg.de (C.B.P.); garate@imbi.uni-heidelberg.de (V.G.-C.)

<sup>2</sup> Health Institute Carlos III (ISCIII), 28029 Madrid, Spain

<sup>3</sup> Department of Basic and Clinical Oncology, Center for Cancer Prevention and Control (CECAN), Medical Faculty, University of Chile, Santiago 380000, Chile; kmarcelain@uchile.cl (K.M.); obarajas@hcuch.cl (O.B.)

<sup>4</sup> Research Unit of Molecular Epidemiology and Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany; waldenberger@helmholtz-muenchen.de

<sup>5</sup> Hospital Regional de Talca, Talca 3460000, Chile; emoralesm@hospitaldetalca.cl (E.M.); cmunozc@hospitaldetalca.cl (C.M.)

<sup>6</sup> Facultad de Medicina, Universidad Católica del Maule, Talca 3460000, Chile; arojasr@ucm.cl

<sup>7</sup> Instituto Nacional del Cáncer, Santiago 7500650, Chile; jretamales@gocchi.org

<sup>8</sup> Hospital de Puerto Montt, Puerto Montt 5480000, Chile; gonzalo.detoro@uach.cl (G.d.T.); allan.vera@araucanianorte.cl (A.V.K.)

<sup>9</sup> Escuela de Tecnología Médica, Universidad Austral de Chile sede Puerto Montt, Puerto Montt 5480000, Chile

<sup>10</sup> Hospital Clínico Universidad de Chile, Santiago 8380456, Chile

<sup>11</sup> Hospital del Salvador, Santiago 7500922, Chile; mrivera@hsalvador.cl (M.T.R.); acortes@hsalvador.cl (A.C.)

<sup>12</sup> Hospital Padre Hurtado, Santiago 8880456, Chile; dloader@hurtadohosp.cl (D.L.); javiera.saavedra@hurtadohosp.cl (J.S.)

<sup>13</sup> Hospital San Juan de Dios, Santiago 8320000, Chile; lorena.gutierrez@redsalud.gob.cl

<sup>14</sup> Hospital Regional, Arica 1000000, Chile; alejandro.ortega@hjnc.cl

<sup>15</sup> Unidad Registro Hospitalario de Cáncer, Hospital Base de Valdivia, Valdivia 5090146, Chile; enriqueeta.bertran@redsalud.gov.cl

<sup>16</sup> Hospital Base de Valdivia, Valdivia 5090146, Chile; leonardo.bartolotti@redsalud.gob.cl

<sup>17</sup> Hospital San Borja Arriarán, Santiago 8320000, Chile; gablerf@uchile.cl (F.G.); monicam.camposm@redsalud.gob.cl (M.C.)

<sup>18</sup> Hospital Regional Guillermo Grant Benavente, Concepción 4070386, Chile; jualvarado@udec.cl (J.A.); fabriziomosian@udec.cl (F.M.); mspencer@udec.cl (L.S.)

<sup>19</sup> Department of Hematology and Oncology, Center for Cancer Prevention and Control (CECAN), School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile; bnervi@uc.cl

<sup>20</sup> Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7650568, Chile; carvajalh.daniel@gmail.com

<sup>21</sup> Departamento de Cirugía, Universidad de La Frontera, Temuco 4780000, Chile; hector.losada@ufrontera.cl

<sup>22</sup> Hospital de Rancagua, Rancagua 2820000, Chile; halmau@clinicasamedica.cl (M.A.); pfernandez@clinicasamedica.cl (P.F.)

<sup>23</sup> Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08007 Barcelona, Spain; jordiolloquequi@ub.edu

<sup>24</sup> Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Talca 3460000, Chile

<sup>25</sup> Instituto de Alta Investigación, Tarapacá University, Arica 1000000, Chile; psalinias@gestion.uta.cl

<sup>26</sup> Laboratory of Biostatistics for Precision Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France



**Citation:** Ceballos, F.; Boekstegers, F.; Scherer, D.; Barahona Ponce, C.; Marcelain, K.; Gárate-Calderón, V.; Waldenberger, M.; Morales, E.; Rojas, A.; Muñoz, C.; et al. Inbreeding and Gallbladder Cancer Risk: Homozygosity Associations Adjusted for Indigenous American Ancestry, BMI, and Genetic Risk of Gallstone Disease. *Cancers* **2024**, *16*, 4195. <https://doi.org/10.3390/cancers16244195>

Academic Editors: David A. Geller and Luca Roncucci

Received: 7 October 2024

Revised: 3 December 2024

Accepted: 6 December 2024

Published: 17 December 2024



**Copyright:** © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

\* Correspondence: ceballoscamina@gmail.com (F.C.); lorenzo@imbi.uni-heidelberg.de (J.L.B.); Tel.: +49-06221-56-4180 (J.L.B.)

**Simple Summary:** We analyzed genetic data from over 4000 Chileans, a highly heterogeneous population with one of the highest rates of gallbladder cancer worldwide, to investigate the relationship between runs of homozygosity as a genetic marker for inbreeding, genetic ancestry, and the risk of gallbladder cancer. We found that inbreeding in Chileans is due to a mixture of genetic drift and consanguinity. We detected no direct association between inbreeding and overall gallbladder cancer risk, but sex, age, and genetic predisposition to gallstone disease influenced the association. The diversity of Latin American genomes in ancestry and homozygosity should be carefully considered when studying genetic susceptibility to disease.

**Abstract:** Latin Americans have a rich genetic make-up that translates into heterogeneous fractions of the autosomal genome in runs of homozygosity ( $F_{ROH}$ ) and heterogeneous types and proportions of indigenous American ancestry. While autozygosity has been linked to several human diseases, very little is known about the relationship between inbreeding, genetic ancestry, and cancer risk in Latin Americans. Chile has one of the highest incidences of gallbladder cancer (GBC) in the world, and we investigated the association between inbreeding, GBC, gallstone disease (GSD), and body mass index (BMI) in 4029 genetically admixed Chileans. We calculated individual  $F_{ROH}$  above 1.5 Mb and weighted polygenic risk scores for GSD, and applied multiple logistic regression to assess the association between homozygosity and GBC risk. We found that homozygosity was due to a heterogeneous mixture of genetic drift and consanguinity in the study population. Although we found no association between homozygosity and overall GBC risk, we detected interactions of  $F_{ROH}$  with sex, age, and genetic risk of GSD that affected GBC risk. Specifically, the increase in GBC risk per 1%  $F_{ROH}$  was 19% in men ( $p$ -value = 0.002), 30% in those under 60 years of age ( $p$ -value = 0.001), and 12% in those with a genetic risk of GSD above the median ( $p$ -value = 0.01). The present study highlighted the complex interplay between inbreeding, genetic ancestry, and genetic risk of GSD in the development of GBC. The applied methodology and our findings underscored the importance of considering the population-specific genetic architecture, along with sex- and age-specific effects, when investigating the genetic basis of complex traits in Latin Americans.

**Keywords:** gallbladder cancer; American ancestry; runs of homozygosity; BMI; inbreeding

## 1. Introduction

Gallbladder cancer (GBC) remains an aggressive disease with very limited treatment options and a lack of reliable markers for early detection [1,2]. In 2020, the incidence of GBC was projected to increase by 75% by 2040, underscoring the urgency of characterizing the factors that contribute to GBC development [3]. Currently, the best predictors of GBC risk are the presence of gallstones, age, and sex, with women being more susceptible to the disease.

Large differences in the incidence and mortality of GBC are observed in different populations and geographic regions, challenging our understanding of GBC etiology [4,5]. The highest incidences have been reported in Bolivia (especially around Lake Titicaca), Chile (especially in the southern regions), Peru (especially in the city of Trujillo), Japan, northern India, and New Mexico, USA [1,4]. This geographical clustering suggests a possible link between GBC development and ancestry, particularly in individuals with indigenous Asian and American roots, which may have a genetic, cultural, or mixed origin.

Among these clusters, Chile stands out as the country with the highest GBC incidence, with approximately 27.3 cases per 100,000 individuals [1]. Within Chile, GBC incidence shows considerable heterogeneity, further highlighting the potential role of genetic ancestry in disease susceptibility [6–8]. The relatively simple distribution of ancestry components in Chile facilitates the study of the genetic basis of GBC. The African contribution to the

Chilean genome is limited (<3% on average), and the proportion of European ancestry is particularly high in the central metropolitan region [9–11]. The indigenous American ancestry can be broadly divided into two main components: Aymara–Quechua ancestry in northern Chile, and Mapuche—Huilliche ancestry in the south. Notably, in contrast to Aymara–Quechua ancestry, each 1% increase in the individual proportion of Mapuche–Huilliche ancestry was associated with a 2% increased risk of developing GBC and a 3.7% higher GBC mortality [5]. Consistent with this association, the prevalence of GBC is about 20 times higher in Argentina’s Andean region than in the rest of the country, indicating a possible contribution of indigenous American ancestry to GBC susceptibility in this region as well [3]. Other GBC risk factors such as gallstone disease (GSD), elevated body mass index (BMI), low socioeconomic status, and lifestyle in general could confound the association between indigenous American ancestry and GBC risk, but the results of a recent study suggest a putatively causal effect of Mapuche—Huilliche ancestry on GBC development [12].

Genomic homozygosity, quantified by runs of homozygosity (ROH), i.e., contiguous stretches of homozygous alleles in identical-by-descent status, reflects the demographic history of both individuals and populations and has been shown to influence several complex traits [13]. Large studies found associations between the fraction of the genome in ROH ( $F_{ROH}$ ) and a wide range of phenotypes, including height, BMI, diabetes, heart disease, and subcutaneous adipose tissue [14]. However, most published studies on the effects of inbreeding on human diseases, particularly cancer, showed inconsistent results [13]. Some of the reasons for these inconsistencies are small sample sizes, limited  $F_{ROH}$  variability in the European outbred populations in which most of these studies have been conducted, and the lack of a standardized procedure for ROH analysis. Indigenous American genomes exhibit long stretches of homozygosity, Latin Americans are highly heterogeneous in terms of individual burden of homozygosity, and Chileans have been found to have both high ROH burden and high  $F_{ROH}$  variability [13,15].

In this context, the study of populations characterized by a recent history of genetic admixture and a high and variable degree of inbreeding provides a unique opportunity to explore the relationship between genetic factors and the occurrence of GBC. In this study, we investigate the impact of homozygosity, quantified by individual  $F_{ROH}$  above 1.5 Mb, on GBC risk in Chileans. By simultaneously considering individual type and proportion of indigenous American ancestry, BMI, and genetic risk of GSD, we aim to elucidate the mechanisms underlying geographical clustering of GBC and potentially uncover novel genetic markers for predicting individual GBC risk.

## 2. Materials and Methods

### 2.1. Study Population

The phenotype and genotype data analyzed in this study have been used previously to investigate the relationship between indigenous American ancestry, GBC, GSD, and BMI [12]. The present study included 202 additional GBC patients and 582 additional GSD patients recruited according to a study protocol that complied with the ethical guidelines of the 1975 Declaration of Helsinki. Genotype data were obtained using Illumina Human610-Quad BeadChip and Illumina Infinium Global Screening Array. In 77% of GBC patients, the diagnosis was made after surgical removal of the gallbladder (cholecystectomy), and gallstones were found in around 86% of the GBC patients investigated. GSD patients were individuals who underwent cholecystectomy for symptomatic gallstones. The remaining study participants belonged to population-based studies with a BMI distribution that was representative of the general Chilean population [12] (see Supplementary Table S1).

All participants provided written informed consent prior to enrolment in the study, using a consent form reviewed by a representative of the Chilean Foundation of Gastrointestinal Cancer Patients. This representative is also a permanent member of the External Advisory Board of the European–Latin American Consortium towards Eradication of Preventable Gallbladder Cancer (EULAT Eradicate GBC), which meets annually to discuss

project objectives, progress, and the relevance of the project results to society. The EULAT Eradicate GBC dissemination videos are available in Aymara, Quechua, and Mapudungun, the language of the Mapuche people. To improve the communication of study results related to ancestry, we organized a symposium at the joint meeting of the Chilean Genetics Society and the Chilean Society of Evolution and recently held a summer school on ancestry and molecular health.

## 2.2. ROH Calling

ROH longer than 300 Kb were called using PLINK v1.9 software [16] and the following parameters: *--homozyg-snp* 30 (minimum number of single nucleotide polymorphisms [SNPs] a ROH must have), *--homozyg-kb* 300 (length of sliding window in Kb), *--homozyg-density* 30 (minimum density required to consider a ROH, 1 SNP in 30 Kb), *--homozyg-window-snp* 30 (number of SNPs the sliding window must have), *--homozyg-gap* 1000 (length in Kb between two SNPs to be considered in two different segments), *--homozyg-window-het* 1 (number of heterozygous SNPs allowed in a window), *--homozyg-window-missing* 5 (number of missing calls allowed in a window), *--homozyg-window-threshold* 0.05 (proportion of the overlapping window that must be called homozygous to define a given SNP as “in a homozygous segment”). No linkage disequilibrium pruning was performed. We filtered out SNPs with minor allele frequencies < 0.01 and those deviating from Hardy–Weinberg (H-W) proportions with a *p*-value < 0.001. These parameters have already been used and validated in large-scale published studies, and they have been shown to call ROH corresponding to autozygous segments in which all SNPs (including those not present on the genotyping array) are homozygous by descent [13,14].

## 2.3. Estimating Inbreeding and Its Origin

Inbreeding can arise from departure from panmixia, which involves systematic inbreeding, also known as consanguinity ( $F_{IS}$ ), or from genetic isolation and a small effective population size, genetic drift ( $F_{ST}$ ), which leads to panmictic inbreeding [17,18]. Systematic inbreeding directly affects the H-W equilibrium of a population, but its effects can be reversed within a single generation of panmictic breeding. In contrast, panmictic inbreeding does not affect H-W proportions, but leads to a reduction in genetic variability within the population through allele loss [19]. The total inbreeding coefficient  $F_{IT}$  is defined as the probability that an individual receives two alleles identical by descent:  $(1 - F_{IT}) = (1 - F_{IS})(1 - F_{ST})$  [20,21]. Traditionally,  $F_{IT}$  has been measured using deep genealogies. Here, we considered  $F_{ROH}$ , or the genomic inbreeding coefficient, as a proxy for  $F_{IT}$  and estimated  $F_{IS}$  using SNP data.

$F_{IS}$  is the average SNP homozygosity within an individual relative to the expected homozygosity of alleles randomly drawn from the population. PLINK estimates  $F_{IS}$  using the following expression:

$$F_{IS} = \frac{O(HOM) - E(HOM)}{N - E(HOM)}, \quad (1)$$

where  $O(HOM)$  is the observed number of homozygous SNPs,  $E(HOM)$  is the expected number of homozygous SNPs considering H-W proportions, and  $N$  is the total number of non-missing genotyped SNPs.  $F_{IS}$  thus measures inbreeding in the current generation, with  $F_{IS} = 0$  indicating random mating,  $F_{IS} > 0$  indicating consanguinity, and  $F_{IS} < 0$  indicating inbreeding avoidance.

$F_{ROH}$  quantifies the actual proportion of the autosomal genome that is autozygous over and above a specific minimum length ROH threshold. When analyzing  $ROH > 1.5$  Mb,  $F_{ROH}$  correlates strongly ( $r = 0.86$ ) with inbreeding coefficients obtained from six-generation pedigrees [22]:

$$F_{ROH} = \frac{\sum_{i=1}^n ROH > 1.5 \text{ Mb}}{3 \text{ Gb}} \quad (2)$$

#### 2.4. Testing Inbreeding Depression

Traditionally, inbreeding depression refers to the decline in the evolutionary fitness of an individual or population due to an increase in homozygosity as a result of inbreeding. This concept has now been extended to any complex trait, describing the change in average phenotypic value within a population due to inbreeding. When considering the combined influence of all loci affecting a specific trait, in terms of the additive combination of genotypic values, the average trait value within a population with an inbreeding coefficient ( $F$ ) is given by the following [23]:

$$M_F = M_0 - 2F \sum d_i \bar{p}_i \bar{q}_i, \quad (3)$$

where  $M_0$  stands for the average population value prior to inbreeding,  $d$  is the genotypic value of heterozygotes, and  $p$  and  $q$  denote the allele frequencies.

This equation illustrates that inbreeding leads to a change in the average trait value within a population when the cumulative genotypic value of heterozygotes ( $d$ ) is not zero, indicating that the trait must exhibit some form of directional dominance or overdominance in its genetic architecture. Furthermore, for additive locus combinations, the change in the mean due to inbreeding is directly proportional to the inbreeding coefficient [24]. This knowledge enables us to identify instances of inbreeding depression in complex traits showing directional dominance through regression analysis, provided that the population under study has a certain degree of inbreeding. It is important to note that the underlying genetic architecture of a trait, including the effects of inbreeding depression, may be different in different populations. The severity of inbreeding depression and the genetic basis of a trait depend on factors such as selection pressure, environmental influences, and population structure, which lead to variations in genetic frequencies between populations.

In this study, we assessed the relationship between  $F_{ROH}$  and GBC risk using multiple logistic regression. GBC status was regressed against  $F_{ROH}$  as an independent variable, along with age, age<sup>2</sup>, biological sex, education, proportions of Aymara—Quechua and Mapuche—Huilliche ancestry, BMI, and genetic risk of GSD disease, characterized by a weighted polygenic risk score based on six GSD-associated variants previously proposed for the Chilean population [25]. The interactions of  $F_{ROH}$  with sex, age, genetic risk of GSD, and ancestry proportions were also tested.

### 3. Results

Table 1 shows the main characteristics of the study participants, both overall and stratified by specific subgroups, including GBC patients (15.3% of the study participants), GSD patients (23.3%), and individuals classified as overweight ( $BMI > 25 \text{ kg/m}^2$ ; 61.5%). On average, GBC patients were more often female, older, less educated, and had a higher proportion of indigenous Mapuche—Huilliche ancestry than the total study population, while differences in genetic risk of GSD (quantified by weighted polygenic risk scores) and  $F_{ROH}$  were rather small (overlapping interquartile ranges [IQR]).


Figure 1 shows the geographical distribution of GBC and GSD odds ratios (ORs, using the Santiago metropolitan region as the reference), BMI and  $F_{ROH}$  in the study population. The ratio of GBC and GSD patients was highest in the de los Lagos and de los Ríos regions. Study participants from the de los Ríos region had the highest mean BMI, and  $F_{ROH}$  was particularly high in the Araucanía, de los Lagos, and de los Ríos regions. Supplementary Table S1 presents the characteristics of the study participants, who were classified into six categories of genetic ancestry (European: European proportion > 0.70; Aymara—Quechua: Aymara—Quechua proportion > 0.70; Aymara—Quechua—European: Aymara—Quechua proportion 0.35–0.70; Mapuche—Huilliche: Mapuche—Huilliche proportion > 0.70; Mapuche—Huilliche—European: Mapuche—Huilliche proportion 0.35–0.70; Other admixture: remaining study participants). The Aymara—Quechua group showed the highest median  $F_{ROH}$  (0.028, IQR [0.023–0.033]), followed by Mapuche—Huilliche individuals

(0.026, IQR [0.022–0.039]), compared with a median  $F_{ROH}$  of 0.007 (IQR [0.005–0.011]) for individuals in the “Other admixture” category.

**Table 1.** Main characteristics of the study participants summarized by absolute and relative frequencies for categorical variables and by medians and interquartile ranges for continuous variables.

Variable	Level	All Participants n = 4029 (100%)		Gallbladder Cancer Patients n = 616 (15.3%)		Gallstone Disease Patients n = 933 (23.2%)		Overweight Participants n = 2254 (61.5%)	
Sex	Male	1744	43.3%	147	23.9%	189	20.3%	1045	46.4%
	Female	2284	56.7%	469	76.1%	744	79.7%	1209	53.6%
Age	Continuous	37	26–58	60	49–67	56	41–66	40	28–59
Education	Primary and informal schooling	515	12.7%	276	45.3%	302	32.4%	285	12.6%
	Secondary	1749	43.4%	207	33.6%	284	30.4%	968	42.9%
	Technical	156	3.9%	27	4.4%	50	5.3%	75	3.4%
	Postgraduate	69	1.7%	3	0.5%	7	0.8%	42	1.9%
	University	532	13.2%	39	6.3%	77	8.3%	280	12.4%
	Missing	1008	25.0%	64	10.4%	213	22.8%	604	26.8%
Ancestry group	Aymara–Quechua	111	2.7%	7	1.1%	12	1.3%	57	2.5%
	Aymara–Quechua–European	197	4.9%	3	0.5%	8	0.9%	114	5.1%
	European	113	2.8%	15	2.5%	23	2.5%	51	2.3%
	Mapuche–Huilliche	82	2.1%	39	6.3%	39	4.2%	48	2.1%
	Mapuche–Huilliche–European	1885	46.8%	341	55.4%	516	55.3%	1069	47.4%
	Other admixture	1641	40.7%	211	34.3%	335	35.9%	915	40.6%
Genetic risk of gallstone disease	Continuous	0.45	0.38–0.53	0.45	0.39–0.54	0.47	0.39–0.54	0.45	0.38–0.54
$F_{ROH}$	Continuous	0.009	0.006–0.013	0.011	0.008–0.016	0.011	0.008–0.014	0.012	0.009–0.017


**Overweight participants:** Body mass index > 25 kg/m<sup>2</sup>. **Aymara–Quechua:** Aymara–Quechua proportion > 0.70. **Aymara–Quechua–European:** Aymara–Quechua proportion 0.35–0.70. **European:** European proportion > 0.70. **Mapuche–Huilliche:** Mapuche–Huilliche proportion > 0.70. **Mapuche–Huilliche–European:** Mapuche–Huilliche proportion 0.35–0.70. **Other admixture:** Remaining study participants. **Genetic risk of gallstone disease:** Weighted polygenic risk score based on the six risk variants identified for Latin Americans by Joshi et al. and their corresponding summary statistics for Chileans provided by Bustos et al.  **$F_{ROH}$ :** Sum of runs of homozygosity above 1.5 Mb divided by the total length of the autosomal genome.



**Figure 1.** Maps of Chile showing the distribution of GBC, gallstone disease, BMI, and  $F_{ROH}$ .

### 3.1. Relationship Between ROH Length and Origin, Genetic Ancestry, and GBC Risk


ROH size correlates strongly with the time of origin of homozygosity runs. Long ROH indicates a common ancestor a few generations ago, while short ROH points to the shared ancestor being more distant, with recombination over more generations having a greater effect on ROH size. Figure 2 shows the distribution of ROH size for the five categories of genetic ancestry and by GBC status. Individuals with a high proportion of indigenous American ancestry exhibited on average large sums of short ROH (0.3–1 Mb), reflecting ancient inbreeding (Aymara–Quechua:  $497 \text{ Mb} \pm 52.6$ , Mapuche–Huilliche:  $468 \text{ Mb} \pm 70.1$ , in contrast to  $230 \text{ Mb} \pm 25.2$  for “Other admixture”; see also Supplementary Table S2). Analysis of variance (ANOVA) confirmed higher total sums of ROH below 1 Mb in both “Aymara–Quechua” and “Mapuche–Huilliche” individuals than in the “Other admixture” category ( $p\text{-value} < 2.6 \times 10^{-16}$ ). ROH over 8 Mb represent young autozygous haplotypes that arose less than five generations ago and thus reflect cultural practices such as consanguinity, extreme endogamy, and/or reproductive isolation. Mapuche–Huilliche individuals had a higher total sum of ROH over 8 Mb than the other ancestry categories (ANOVA  $p\text{-value} = 8.2 \times 10^{-13}$  Figure 2). As for the relationship between ROH size and GBC status, neither the differences in the total sum of ROH below 1 Mb nor the differences in the total sum of ROH above 8 Mb reached the 0.05 statistical significance level.



**Figure 2.** ROH size distribution by population (panel A) and gallbladder cancer (GBC) status (panel B). Represented are ROH total sums over six classes of ROH tract lengths:  $0.3 \leq \text{ROH} < 0.5 \text{ Mb}$ ,  $0.5 \leq \text{ROH} < 1 \text{ Mb}$ ,  $1 \leq \text{ROH} < 2 \text{ Mb}$ ,  $2 \leq \text{ROH} < 4 \text{ Mb}$ ,  $4 \leq \text{ROH} < 8 \text{ Mb}$  and  $\text{ROH} \geq 8 \text{ Mb}$ . Plots are organized by population and presence of GBC. Study individuals were categorized into six groups as follows: European: European proportion  $> 0.70$ ; Aymara–Quechua: Aymara–Quechua proportion  $> 0.70$ ; Aymara–Quechua–European: Aymara–Quechua proportion  $0.35–0.70$ ; Mapuche–Huilliche: Mapuche–Huilliche proportion  $> 0.70$ ; Mapuche–Huilliche–European: Mapuche–Huilliche proportion  $0.35–0.70$ ; Other admixture: remaining study participants.

We investigated the origin of ROH using two complementary approaches. We examined the relationship between the number and sum of ROH above 1.5 Mb, as well as the relationship between F<sub>ROH</sub> and the systematic inbreeding coefficient (FIS). In the upper panels of Figure 3, the relative contributions of genetic drift and consanguinity on homozygosity are examined by comparing the number of ROH (NROH) and the sum of ROH (SROH) per individual genome. When genetic drift is strong, both NROH and SROH are proportionately high. Conversely, consanguinity primarily results in long ROH, leading to a disproportionate increase in SROH compared with NROH. The diagonal lines in the upper panels of Figure 3 represent the expected relationship between NROH

and SROH for an outbred population with no evidence of consanguinity. Individuals with high NROH/SROH values along the diagonal show a high degree of autozygosity caused by genetic drift, while deviations to the right of the diagonal indicate consanguinity. Among the categories of genetic ancestry, especially the “Mapuche–Huilliche”, “Mapuche–Huilliche–European”, and “Other admixture” individuals showed substantial homozygosity attributable to heterogeneous combinations of consanguinity and genetic drift. Comparison with simulated consanguineous mating (Figure 3, upper panel left; second cousins in green, first cousins in yellow, avuncular mating [uncle–niece, aunt–nephew, double first cousin] in orange, and incest [brother–sister, parent–offspring] in red) revealed some highly consanguineous individuals in the categories “Mapuche–Huilliche” and “Mapuche–Huilliche–European”. The examination of individuals with and without GBC (Figure 3, upper panel right) showed marked heterogeneity within groups, but no notable differences between individuals with/without GBC with regard to their ROH origin.



**Figure 3.** Assessment of ROH origins by population (left panels) and gallbladder cancer (GBC) status (right panels). Study individuals were categorized into six groups as follows: European: European proportion > 0.70; Aymara–Quechua: Aymara–Quechua proportion > 0.70; Aymara–Quechua–European: Aymara–Quechua proportion 0.35–0.70; Mapuche–Huilliche: Mapuche–Huilliche proportion > 0.70; Mapuche–Huilliche—European: Mapuche–Huilliche proportion 0.35–0.70; Other admixture: remaining study participants. Upper panels: Mean number of ROH versus sum of ROH > 1.5 Mb for each individual. The dotted straight lines represent the linear regression of the

number of ROH on the sum of ROH in individuals of African ancestry in the southwestern USA (ASW) and African Caribbean in Barbados (ACB) from the 1000 Genomes Project that represent admixed and thus relatively outbred populations. Simulations of the number and sum of ROH > 1.5 Mb for the offspring of different consanguineous matings are also shown in the left plot. The color of the dots represents the type of consanguineous mating: second cousin (green), first cousin (yellow), avuncular (uncle–niece, aunt–nephew, double first cousin; (orange), incest (brother–sister, parent–offspring; (red). For each mating type, 5000 individuals were simulated. Note that the simulation did not include drift, but the degree of right shift can be projected to cases where there is a non-zero level of autozygosity due to drift. Lower panels: Systematic inbreeding coefficient ( $F_{IS}$ ) versus the  $F_{ROH}$ -based inbreeding coefficient.  $F_{IS}$  represents the average individual single nucleotide polymorphism homozygosity relative to the expected homozygosity of alleles randomly drawn from the population, which was calculated using the -het function in PLINK. The dotted diagonal represents  $F_{IS} = F_{ROH}$ , and the dotted horizontal line shows  $F_{IS} = 0$ .

In the lower panels of Figure 3, the mean  $F_{IS}$  is plotted against the  $F_{ROH}$  for each study participant. The diagonal line ( $F_{IS} = F_{ROH}$ ) and the horizontal line ( $F_{IS} = 0$ ) delineate three distinct regions. (1) Individuals near the diagonal line have a pronounced component of systematic inbreeding or  $F_{IS}$ , indicating consanguinity. (2) Individuals near the horizontal line show panmictic inbreeding, caused mainly by genetic drift. (3) Negative  $F_{IS}$  values indicate that low effective population size, isolation, and genetic drift play an important role. The lower panels of Figure 3 show heterogeneity of ROH origin between and within populations and illustrate that consanguinity plays an important role in the origin of homozygosity in highly inbred individuals. Consistent with the upper right panel, differences between individuals with/without GBC in terms of ROH origin are not apparent in the lower right panel.

### 3.2. Effects of the Homozygosity in the Prevalence of GBC


As presented in Table 2, statistical analysis confirmed the increased risk of GBC in women per year (but a decreasing risk per year<sup>2</sup>) in individuals with low levels of education, with increasing proportions of Mapuche–Huilliche ancestry, and with increasing genetic susceptibility for GSD. However, we found no association between  $F_{ROH}$  and overall GBC risk. Similarly, no effects of homozygosity on BMI or GSD were observed, as shown in Supplementary Table S3. Nevertheless, we identified interactions of  $F_{ROH}$  with sex, age, and genetic risk of GSD that affected GBC risk. In light of these intriguing results, we further examined the impact of  $F_{ROH}$  after stratifying the complete dataset by sex (Supplementary Table S4), age (Supplementary Table S5), and genetic risk of GSD (Supplementary Table S6).

Figure 4 depicts the ORs from the different analyses conducted. The forest plot illustrates a notable influence of  $F_{ROH}$  on GBC risk for specific subsets of the population: males, individuals under 60 years of age (mean age at GBC diagnosis in the study population), and those with a higher-than-average genetic risk of GSD. Among males, GBC risk increased by 19% for every 1% rise in  $F_{ROH}$  (OR = 1.19, 95% CI 1.01–1.39,  $p$ -value = 0.002), but we found no association between  $F_{ROH}$  and GBC risk in women. Considering an age cutoff of 60 years (average age at the time of GBC diagnosis), we observed a 30% increase in GBC risk for each 1% increase in  $F_{ROH}$  (OR = 1.30, 95% CI 1.09–1.98) only among individuals younger than 60 years. Stratifying by median genetic risk of GSD, which corresponded to a weighted polygenic risk score of 0.445, individuals with a higher than median genetic susceptibility to GSD showed a 12% increased risk of GBC for every 1% elevation in  $F_{ROH}$  (OR = 1.12, 95% CI 1.03–1.21).

**Table 2.** Relative risk of gallbladder cancer by potential confounders and FROH.

Variable	Level	OR	95% CI	p-Value
Sex	Male	Baseline		
	Female	<b>3.48</b>	2.64–4.62	$2.1 \times 10^{-16}$
Age	Per year	<b>1.18</b>	1.12–1.26	$1.4 \times 10^{-14}$
	Age <sup>2</sup>	<b>0.99</b>	0.99–1.00	$2.6 \times 10^{-16}$
Education	Primary and informal schooling	<b>2.65</b>	1.65–4.31	$1.2 \times 10^{-4}$
	Secondary	Baseline		
	Technical	0.47	0.20–1.07	
	Postgraduate	0.22	0.03–1.07	
	University	0.57	0.32–1.02	
	Missing	<b>0.14</b>	0.09–0.22	
BMI	Normal	Baseline		0.35
	Overweight	1.34	0.89–2.04	
	Obesity	1.27	0.83–1.97	
Ancestry	Per Aymara–Quechua %	<b>0.97</b>	0.96–0.98	0.04
	Per Mapuche–Huilliche %	<b>1.02</b>	1.01–1.05	$1.2 \times 10^{-5}$
Genetic risk of gallstone disease	Per doubling in disease prevalence	<b>2.75</b>	1.49–4.94	0.001
F <sub>ROH</sub>	Per 1%	1.07	0.98–1.15	0.26

**OR:** Odds ratio; **CI:** Confidence interval; **p-value:** Probability value; **BMI:** Body mass index; **Normal:** BMI  $\leq 25$  kg/m<sup>2</sup>; **Overweight:** BMI 25–29.9 kg/m<sup>2</sup>; **Obesity:** BMI  $> 30$  kg/m<sup>2</sup>; **Aymara–Quechua %:** Proportion of northern Chilean Native American ancestry; **Mapuche–Huilliche %:** Proportion of Mapuche–Huilliche ancestry; **Genetic risk of gallstone disease:** Weighted polygenic risk score based on the six risk variants identified for Latin Americans by Joshi et al. and their corresponding summary statistics for Chileans provided by Bustos et al.; **F<sub>ROH</sub>:** Sum of runs of homozygosity above 1.5 Mb divided by the total length of the autosomal genome. Bold type indicates that the 95% CI does not include 1.00.



**Figure 4.** Inbreeding and gallbladder cancer (GBC) risk. Odds ratios (ORs) per 1% F<sub>ROH</sub> with probability values and 95% confidence intervals are shown for the whole study and stratified by biological sex, age (considering a cut-off point of 60 years) and genetic risk of gallstone disease (weighted polygenic risk score [PRS] based on the six risk variants identified for Latin Americans by Joshi et al. and their corresponding summary statistics for Chileans provided by Bustos et al., considering the median score of 0.445 as cut-off point).

#### 4. Discussion

GBC continues to pose a significant challenge to the healthcare system in high incidence areas due to the absence of early detection markers and the very limited treatment options for advanced disease [26]. It has been postulated that GBC takes 10–20 years to develop, typically following the sequence of gallstones and inflammation, gallbladder dysplasia, and GBC, and that the surgical removal of the gallbladder (cholecystectomy) is an effective option for prevention before the onset of symptoms, emphasizing the urgent need to identify and exploit risk and early diagnosis factors associated with this malignancy. The highly variable prevalence of GBC in different subpopulations and geographic regions, as well as the familial aggregation of GBC [27], suggest a genetic component to GBC risk. GBC is the third leading cause of death in Japanese living in the USA and the third leading malignancy in the Native American population, according to the New Mexico Tumor Registry (<https://hsc.unm.edu/new-mexico-tumor-registry/> last checked 26 February 2024). Conversely, GBC appears to be rare in people of African descent. Importantly for this study, clear associations have been reported between Asian and indigenous American ancestries and increased susceptibility to GBC. However, even within these broad ethnic groups, the distribution of GBC is very heterogeneous. Gallstones are an important risk factor for GBC, and the proportion of GBC patients with gallstones also shows great ethnic variability: in contrast to the 86% of Chilean GBC patients with gallstones in the present study, only 33% of Indian GBC patients had gallstones in a large genome-wide association study [1,28].

Inbreeding has been associated with GBC risk in the past. For example, the Abiquiu community in the Chama Valley region of New Mexico has both a high prevalence of GBC and endogamous mating practices that have led to high levels of inbreeding, suggesting a potential link between homozygosity and GBC susceptibility [4]. In order to understand the biological mechanisms linking homozygosity and GBC risk, large studies with sufficient statistical power are needed to refine the current findings, based on global homozygosity, by examining local homozygosity in specific chromosomal regions, e.g., by analysis of ROH islands [22,29–32].

In Chile, one of the countries with the highest GBC incidence in the world, the individual proportion of overall indigenous American ancestry does not correlate with GBC mortality, but the specific indigenous Mapuche subcomponent (the Mapuche are the largest indigenous people, living mainly in central and southern Chile) is strongly associated with GBC incidence and mortality. Recent studies suggest that gallstone disease mediates the association between Mapuche–Huilliche ancestry and GBC risk in Chileans, speculating that genetic selection during periods of nutritional and caloric insufficiency has now resulted, in a hypercaloric environment, in an increased predisposition to gallstone formation (12). Considering this scenario, we investigated the genetic contribution to GBC risk from a new perspective—assessing the potential influence of ancient and recent inbreeding quantified by the genomic distribution of ROH. Our study is the first attempt to examine the relationship between GBC, homozygosity (quantified as the fraction of the genome in ROH over 1.5 Mb), and the proportion of indigenous American ancestry present in Chile. Of note, homozygosity exhibited a considerable degree of variability across the six categories of genetic ancestry defined in the present study, which is consistent with previous large-scale investigations.

Our study provides novel insights into the interplay of genetic ancestry, homozygosity, and GBC development. The particular genetic tapestry of Chile, woven through a complex history of admixture and migration, provides an optimal framework for such studies. The six defined ancestry categories exhibited different characteristics in terms of ROH, mirroring their unique genetic history. This variability translates into improved statistical power, which distinguishes our study from analyses based on European cohorts. Remarkably, the groups with indigenous American ancestry, in particular Aymara–Quechua individuals, displayed larger average ROH sizes, which can be attributed to ancient inbreeding.

In contrast, the presence of longer ROH in the Mapuche–Huilliche category points to consanguinity, shedding light on the diverse origins of homozygosity in these populations.

The crux of our study was to investigate the impact of genomic homozygosity, quantified through  $F_{ROH}$ , on GBC risk. We simultaneously considered  $F_{ROH}$ , the proportion of Aymara–Quechua and Mapuche–Huilliche ancestry, BMI, genetic risk of GSD, and education level using logistic regression to assess the effect of homozygosity on GBC risk while accounting for potential confounders. The relevance of considering potential cultural and social confounding, as we did in our study by accounting for educational attainment and individual ancestry proportions, was well illustrated in a comprehensive meta-analysis that scrutinized full-sibling data. Remarkably,  $F_{ROH}$  differences between siblings were solely due to Mendelian segregation and remained unaffected by cultural and socioeconomic influences. On average,  $F_{ROH}$  effect estimates derived from sibling relationships were 22% lower than their population-based counterparts for all trait analyses, possibly reflecting the contribution of non-genetic confounders.

In contrast to comparisons between separate ethnic groups (e.g., individuals of European versus Mapuche ancestry), our study relied on data from genetically admixed Chileans with continuous gradients of homozygosity and ancestry, which added robustness to our findings by attenuating the influence of sociocultural confounders. Although no overarching association emerged across the entire dataset, we were able to unveil strong interaction effects between  $F_{ROH}$  and sex, age, and genetic risk of GSD. Intriguingly, the results suggested a notable influence of  $F_{ROH}$  on the development of GBC in certain population groups, particularly men, individuals under 60 years of age (both men and women), and those with genetic predisposition to gallstones. Notably, the absence of a  $F_{ROH}$  effect in women points to intricate gender differences in GBC development. Sex-specific inbreeding effects have already been observed, underscoring the distinct genetic architecture of numerous traits in males and females [14,33]. Traits such as height, weight, BMI, subcutaneous adipose tissue, low-density lipoprotein cholesterol, and total cholesterol are influenced by sex-specific effects in populations from Africa and other regions worldwide [14]. ROH effects have recently been linked to hospitalization, disease severity, and critical illness risk due to SARS-CoV-2 infection, with these effects being notably more pronounced in males, particularly older men [33]. This phenomenon has been linked to homozygosity in large genomic regions enriched in genes involved in coagulation and inflammatory response pathways. Further research is needed to understand why sex-specific ROH differences are also observed in susceptibility to gallbladder cancer.

We found no interaction between the Mapuche–Huilliche subcomponent of indigenous American ancestry and  $F_{ROH}$ , suggesting that inbreeding affects GBC risk independent of genetic ancestry.

## 5. Conclusions

In conclusion, the present study indicated a complex interplay between  $F_{ROH}$  and GBC risk, pointing to stronger inbreeding effects in men, individuals younger than 60 years, and persons with an increased genetic risk of GSD. The replication of these results in an independent cohort, ideally with a larger study population and including additional sociocultural covariates, would undoubtedly underpin the robustness of our findings. The results indicated that Mapuche–Huilliche ancestry and inbreeding act as independent determinants of genetic susceptibility to GBC, which is important from both a scientific and a preventive perspective. Our study contributes to a deeper understanding of the multifaceted factors underlying the development of GBC and sets the stage for further investigation of the complex interplay between homozygosity, genetic ancestry, and disease susceptibility.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/cancers16244195/s1>, Table S1. Characteristics of study participants by ancestry. Table S2. Relative risk of gallbladder cancer, gallstone disease and overweight from univariate and multiple logistic regression analyses. Table S3. Relative risk of gallbladder cancer from multiple logistic regression analyses stratified by sex. Table S4. Relative risk of gallbladder

cancer from multiple logistic regression analyses stratified by age. Table S5. Relative risk of gallstone disease from multiple logistic regression analysis.

**Author Contributions:** Conceptualization: F.C., F.B. and J.L.B.; data curation: F.B., C.B.P., K.M., V.G.-C., M.W., E.M., A.R., C.M., J.R., G.d.T., A.V.K., O.B., M.T.R., A.C., D.L., J.S., L.G., A.O., M.E.B., L.B., F.G., M.C., J.A., F.M., L.S., B.N., D.C.-H., H.L., M.A., P.F., J.O. and P.S.; formal analysis: F.C. and F.B.; investigation: F.C.; methodology: F.C., F.B., F.B., C.B.P., D.S. and M.W.; supervision: J.L.B.; writing—original draft: F.C.; writing—review and editing: J.L.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by the European Union’s Horizon 2020 research and innovation program (grant 825741); the Deutsche Forschungsgemeinschaft (DFG; grant LO 1928/11-1, project number 424112940); the Chilean National Research and Development Agency (ANID), Grant/Award Number: FONDAP 152220002 (CECAN); and the Biobank of the University of Chile (BTUCH). With regard to the publication fee, we acknowledge financial support from the DFG within the funding program “Open Access Publikationskosten” and from Heidelberg University. The funders had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

**Institutional Review Board Statement:** This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committees of Servicio de Salud Metropolitano Oriente, Santiago de Chile (#06.10.2015, #08.03.2016 and #12.11.2019), Servicio de Salud Metropolitano Sur Oriente, Santiago de Chile (#15.10.2015 and #05.04.2018), Servicio de Salud Metropolitano Central, Santiago de Chile (#1188-2015), Servicio de Salud Coquimbo, Coquimbo, Chile (#01.04.2016), Servicio de Salud Maule, Talca, Chile (#05.11.2015), Universidad Católica del Maule, Talca, Chile (#102-2020), Servicio de Salud Concepción, Concepción, Chile (ID: 16-11-97 and ID:19-12-111), Servicio de Salud Araucanía Sur, Temuco, Chile (#10.02.2020), Servicio de Salud Valdivia, Valdivia, Chile (ID:438), Centro de Bioética, Universidad del Desarrollo, Clínica Alemana de Santiago, Santiago de Chile (#2018-97, ID 678) and Unidad de Investigación Hospital San Juan de Dios, Santiago de Chile (#6182), the Medical Faculties of Universidad de Chile (approval #123-2012 and #11.10.2012), and Pontificia Universidad Católica de Chile (#11-159).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in this study.

**Data Availability Statement:** Files with the called ROH cannot be made publicly available due to privacy and ethical restrictions (potential de-identification of study participants), but they are available upon request from the corresponding author. The source code to reproduce all the results described is provided as supplementary material and available at [www.biometrie.uni-heidelberg.de/StatisticalGenetics/Software\\_and\\_Data](http://www.biometrie.uni-heidelberg.de/StatisticalGenetics/Software_and_Data) (accessed on 11 December 2024).

**Acknowledgments:** The authors gratefully acknowledge the data storage service SDS@hd supported by the Ministry of Science, Research, and the Arts Baden-Württemberg (MWK) and the German Research Foundation (DFG) through grants INST 35/1314-1 FUGG and INST 35/1503-1 FUGG.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. Eslick, G.D. Epidemiology of gallbladder cancer. *Gastroenterol. Clin. N. Am.* **2010**, *39*, 307–330. [[CrossRef](#)] [[PubMed](#)]
2. Srivastava, K.; Srivastava, A.; Kumar, A.; Mittal, B. Gallbladder cancer predisposition: A multigenic approach to DNA-repair, apoptotic and inflammatory pathway genes. *PLoS ONE* **2011**, *6*, e16449. [[CrossRef](#)]
3. Salazar, M.; Ituarte, C.; Abriata, M.G.; Santoro, F.; Arroyo, G. Gallbladder cancer in South America: Epidemiology and prevention. *Chin. Clin. Oncol.* **2019**, *8*, 32. [[CrossRef](#)] [[PubMed](#)]
4. Devor, E.J.; Buechley, R.W. Gallbladder cancer in Hispanic New Mexicans: I. General population, 1957–1977. *Cancer* **1980**, *45*, 1705–1712. [[CrossRef](#)] [[PubMed](#)]
5. Lorenzo Bermejo, J.; Boekstegers, F.; Gonzalez Silos, R.; Marcelain, K.; Baez Benavides, P.; Barahona Ponce, C.; Muller, B.; Ferreccio, C.; Koshiol, J.; Fischer, C.; et al. Subtypes of Native American ancestry and leading causes of death: Mapuche ancestry-specific associations with gallbladder cancer risk in Chile. *PLoS Genet.* **2017**, *13*, e1006756. [[CrossRef](#)] [[PubMed](#)]
6. Andia, M.E.; Hsing, A.W.; Andreotti, G.; Ferreccio, C. Geographic variation of gallbladder cancer mortality and risk factors in Chile: A population-based ecologic study. *Int. J. Cancer* **2008**, *123*, 1411–1416. [[CrossRef](#)]
7. Bertran, E.; Heise, K.; Andia, M.E.; Ferreccio, C. Gallbladder cancer: Incidence and survival in a high-risk area of Chile. *Int. J. Cancer* **2010**, *127*, 2446–2454. [[CrossRef](#)]

8. Nogueira, L.; Foerster, C.; Groopman, J.; Egner, P.; Koshiol, J.; Ferreccio, C.; Gallbladder Cancer Chile Working, G. Association of aflatoxin with gallbladder cancer in Chile. *JAMA* **2015**, *313*, 2075–2077. [[CrossRef](#)]
9. Reich, D.; Patterson, N.; Campbell, D.; Tandon, A.; Mazieres, S.; Ray, N.; Parra, M.V.; Rojas, W.; Duque, C.; Mesa, N.; et al. Reconstructing Native American population history. *Nature* **2012**, *488*, 370–374. [[CrossRef](#)]
10. Ruiz-Linares, A.; Adhikari, K.; Acuna-Alonso, V.; Quinto-Sanchez, M.; Jaramillo, C.; Arias, W.; Fuentes, M.; Pizarro, M.; Everardo, P.; de Avila, F.; et al. Admixture in Latin America: Geographic structure, phenotypic diversity and self-perception of ancestry based on 7,342 individuals. *PLoS Genet.* **2014**, *10*, e1004572. [[CrossRef](#)]
11. Eyheramendy, S.; Martinez, F.I.; Manevi, F.; Vial, C.; Repetto, G.M. Genetic structure characterization of Chileans reflects historical immigration patterns. *Nat. Commun.* **2015**, *6*, 6472. [[CrossRef](#)] [[PubMed](#)]
12. Zollner, L.; Boekstegers, F.; Barahona Ponce, C.; Scherer, D.; Marcelain, K.; Garate-Calderon, V.; Waldenberger, M.; Morales, E.; Rojas, A.; Munoz, C.; et al. Gallbladder Cancer Risk and Indigenous South American Mapuche Ancestry: Instrumental Variable Analysis Using Ancestry-Informative Markers. *Cancers* **2023**, *15*, 4033. [[CrossRef](#)]
13. Ceballos, F.C.; Joshi, P.K.; Clark, D.W.; Ramsay, M.; Wilson, J.F. Runs of homozygosity: Windows into population history and trait architecture. *Nat. Rev. Genet.* **2018**, *19*, 220–234. [[CrossRef](#)]
14. Clark, D.W.; Okada, Y.; Moore, K.H.S.; Mason, D.; Pirastu, N.; Gandin, I.; Mattsson, H.; Barnes, C.L.K.; Lin, K.; Zhao, J.H.; et al. Associations of autozygosity with a broad range of human phenotypes. *Nat. Commun.* **2019**, *10*, 4957. [[CrossRef](#)] [[PubMed](#)]
15. Mooney, J.A.; Huber, C.D.; Service, S.; Sul, J.H.; Marsden, C.D.; Zhang, Z.; Sabatti, C.; Ruiz-Linares, A.; Bedoya, G.; Costa Rica/Colombia Consortium for Genetic Investigation of Bipolar Endophenotypes; et al. Understanding the Hidden Complexity of Latin American Population Isolates. *Am. J. Hum. Genet.* **2018**, *103*, 707–726. [[CrossRef](#)] [[PubMed](#)]
16. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **2007**, *81*, 559–575. [[CrossRef](#)]
17. Jacquard, A. Inbreeding—One word, several meanings. *Theor. Popul. Biol.* **1975**, *7*, 338–363. [[CrossRef](#)]
18. Templeton, A.R.; Read, B. Inbreeding, One Word, Several Meanings, Much Confusion. *Biol. Conserv.* **1996**, *75*, 311.
19. Hedrick, P.W. *Genetics of Populations*; Jones and Bartlett Publishers: Sudbury, MA, USA, 2005.
20. Hartl, D.L.; Clark, A.G. *Principles of Population Genetics*; Sinauer Associates: Sunderland, MA, USA, 2007.
21. Weir, B.S. Estimating F-statistics: A historical view. *Br. J. Philos. Sci.* **2012**, *79*, 637–643. [[CrossRef](#)]
22. McQuillan, R.; Leutenegger, A.L.; Abdel-Rahman, R.; Franklin, C.S.; Pericic, M.; Barac-Lauk, L.; Smolej-Narancic, N.; Janicijevic, B.; Polasek, O.; Tenesa, A.; et al. Runs of homozygosity in European populations. *Am. J. Hum. Genet.* **2008**, *83*, 359–372. [[CrossRef](#)]
23. Falconer, D.S.; Mackay, T.F.C. *Quantitative Genetics Pearson*; Addison Wesley Longman: Harlow, UK, 1996.
24. Charlesworth, D.; Willis, J.H. The genetics of inbreeding depression. *Nat. Rev. Genet.* **2009**, *10*, 783–796. [[CrossRef](#)] [[PubMed](#)]
25. Barahona Ponce, C.; Scherer, D.; Brinster, R.; Boekstegers, F.; Marcelain, K.; Garate-Calderon, V.; Muller, B.; de Toro, G.; Retamales, J.; Barajas, O.; et al. Gallstones, Body Mass Index, C-Reactive Protein, and Gallbladder Cancer: Mendelian Randomization Analysis of Chilean and European Genotype Data. *Hepatology* **2021**, *73*, 1783–1796. [[CrossRef](#)] [[PubMed](#)]
26. Henley, S.J.; Weir, H.K.; Jim, M.A.; Watson, M.; Richardson, L.C. Gallbladder Cancer Incidence and Mortality, United States 1999–2011. *Cancer Epidemiol. Biomark. Prev.* **2015**, *24*, 1319–1326. [[CrossRef](#)] [[PubMed](#)]
27. Hemminki, K.; Hemminki, A.; Forsti, A.; Sundquist, K.; Li, X. Genetics of gallbladder cancer. *Lancet Oncol.* **2017**, *18*, e296. [[CrossRef](#)]
28. Mhatre, S.; Wang, Z.; Nagrani, R.; Badwe, R.; Chiplunkar, S.; Mittal, B.; Yadav, S.; Zhang, H.; Chung, C.C.; Patil, P.; et al. Common genetic variation and risk of gallbladder cancer in India: A case-control genome-wide association study. *Lancet Oncol.* **2017**, *18*, 535–544. [[CrossRef](#)]
29. Pemberton, T.J.; Absher, D.; Feldman, M.W.; Myers, R.M.; Rosenberg, N.A.; Li, J.Z. Genomic patterns of homozygosity in worldwide human populations. *Am. J. Hum. Genet.* **2012**, *91*, 275–292. [[CrossRef](#)]
30. Lencz, T.; Lambert, C.; DeRosse, P.; Burdick, K.E.; Morgan, T.V.; Kane, J.M.; Kucherlapati, R.; Malhotra, A.K. Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 19942–19947. [[CrossRef](#)]
31. Curtis, D.; Vine, A.E.; Knight, J. Study of regions of extended homozygosity provides a powerful method to explore haplotype structure of human populations. *Ann. Hum. Genet.* **2008**, *72 Pt 2*, 261–278. [[CrossRef](#)]
32. Nothnagel, M.; Lu, T.T.; Kayser, M.; Krawczak, M.; Spain, S.L.; Cazier, J.B.; Houlston, R.; Carvajal-Carmona, L.; Tomlinson, I.; Vine, A.E.; et al. Genomic and geographic distribution of SNP-defined runs of homozygosity in Europeans. *Hum. Mol. Genet.* **2010**, *19*, 2927–2935. [[CrossRef](#)]
33. Cruz, R.; Diz-de Almeida, S.; López de Heredia, M.; Quintela, I.; Ceballos, F.C.; Pita, G.; Lorenzo-Salazar, J.M.; González-Montelongo, R.; Gago-Domínguez, M.; Sevilla Porras, M.; et al. Novel genes and sex differences in COVID-19 severity. *Hum. Mol. Genet.* **2022**, *31*, 3789–3806. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.